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The emergence of new methods for reprogramming of adult somatic cells into induced pluripotent stem cells (iPSC) led to the
development of new approaches in drug discovery and regenerative medicine. Investigation of the molecular mechanisms
underlying the self-renewal, expansion and differentiation of human iPSC (hiPSC) should lead to improvements in the
manufacture of safe and reliable cell therapy products. The goal of our study was qualitative and quantitative proteomic
characterizations of hiPSC by means of electrospray ionization (ESI)-MSe and MALDI-TOF/TOF mass spectrometry (MS).
Proteomes of hiPSCs of different somatic origins: fibroblasts and peripheral blood CD34+ cells, reprogrammed by the same
technique, were compared with the original somatic cells and hESC. Quantitative proteomic comparison revealed
approximately 220 proteins commonly up-regulated in all three pluripotent stem cell lines compared to the primary cells.
Expression of 21 proteins previously reported as pluripotency markers was up-regulated in both hiPSCs (8 were confirmed by
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324 N.S. Pripuzova et al.somatic cells discovered by MS were confirmed by Western blot. A panel of 22 candidate marker proteins of hiPSC was
developed and expression of these proteins was confirmed in 8 additional hiPSC lines.
Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Induced pluripotent stem cells (iPSC) are an important
research tool and have a potential to become a significant
source of autologous cells differentiated from iPSC for
therapeutic treatments. However, prior to therapeutic appli-
cation appropriate characterization of human iPSC (hiPSC) is
needed. To date, iPSC have been generated from numerous
somatic cell types including dermal fibroblasts (Lowry et al.,
2008; Takahashi et al., 2007; Yu et al., 2007), lymphocytes
(Staerk et al., 2010; Loh et al., 2010), mesenchymal stem cells
(Zou et al., 2011), endogenous kidney tubular renal epithelial
cells (Montserrat et al., 2012), and CD34+ hematopoietic stem
cells (Loh et al., 2009). It is believed that iPSC of different
somatic origins may be predisposed toward re-differentiation
to a particular cell lineage via “epigenetic memory” (Bar-Nur
et al., 2011; Kim et al., 2010). For instance, it has been
reported that hiPSC derived from hematopoietic stem cells
(CD34+ cells) are particularly suitable for development of
research models and treatments for hematopoietic diseases
(Zou et al., 2011; Merling et al., 2013). Another recent study
has shown that the hepatic lineage epigenetic memory
contributed to the differentiation potential of mouse iPSC
(Lee et al., 2012).
On the mRNA level hiPSC have been found to be clearly
distinguishable from hESC and their expression pattern
becomes closer to that of hESC after extended culture
(Chin et al., 2009); hiPSC have been shown to bear residual
gene expression from the donor cell type (Marchetto et al.,
2009; Ghosh et al., 2010). Recent analysis of 12 established
hiPSC lines has revealed epigenetic and transcriptional
variations among them and has shown that these variations
can have a significant impact on a cell line's ability to
differentiate to a particular cell type (Bock et al., 2011).
The molecular characterization of hiPSC has been per-
formed previously on different biological levels, including:
gene expression profiling, epigenetic evaluation, the role of
miRNAs in pluripotency, and genomic DNA alterations (Muller
et al., 2012; Benevento and Munoz, 2012). However,
quantitative proteomics has not yet been used to character-
ize hiPSC systematically (Munoz et al., 2011; Phanstiel et al.,
2011; Kim et al., 2012; Yamana et al., 2013), and the
molecular differences on the proteome level between hiPSC
of different somatic origins have not been addressed. Sample
preparation and MS-proteomic approaches reported previous-
ly on hiPSC vary significantly (Benevento and Munoz, 2012;
Munoz et al., 2011; Phanstiel et al., 2011; Kim et al., 2012;
Yamana et al., 2013), which complicates direct comparison of
these studies.
The focal point of this study was the analysis of proteomes
of two hiPSC lines at the earlier and later cell culture
passages derived in two different laboratories and of different
somatic origins: CD34+ cells circulating in peripheral blood
(iNC-01) and fibroblasts of healthy donors (SB5-MP1). Both
hiPSC lines were generated using the same reprogrammingtechnique: loxP-flanked excisable polycistronic (human Oct4,
Klf4, Sox2, and c-Myc) STEMCCA lentiviral vector, which
generates transgene-free hiPSC lines upon Cre-mediated
vector excision. iNC-01 cell line was previously used to obtain
functional neutrophils (Sweeney et al., 2014) and SB5-MP1
was successfully used in differentiation into motor neurons
(Grunseich et al., 2014). In parallel, we performed a
quantitative global proteome analysis of H9 hESC line at the
earlier and later passages, as well as of the somatic cell types
(fibroblasts and peripheral blood mononuclear cells (PBMC),
the cell population containing CD34+ hematopoietic stem
cells).
From an analytical perspective, we applied the approach
that combines application of high pressure assisted protein
extraction and a combination of two LC/MS/MS techniques:
electrospray ionization (ESI)-MSe and MALDI-TOF/TOF
(Mindaye et al., 2013a, 2013b). Label-free quantification of
proteins was performed by ESI-MSe using normalization
against an internal reference standard (Silva et al., 2005,
2006). Quantitative and qualitative comparisons of hiPSC/
hESC proteomes with that of somatic cells allowed the
development of a protein marker panel for characterization
of hiPSC, which was successfully tested in 8 more hiPSC lines
of different somatic origins derived in different laboratories
by different reprogramming techniques.
Materials and methods
Cells
Stem cell lines used for ESI-MSe and MALDI-TOF/TOF
analyses are: iNC-01, passage (P) 36 and P53-peripheral
blood CD34+ hematopoietic stem/progenitor cells derived
hiPSC line, previously described (Merling et al., 2013);
SB5-MP1, P22 and P28-adult fibroblasts derived hiPSC line,
previously described (Grunseich et al., 2014); and H9
(WA09), P34 and P48-hESC line obtained from WiCell
Research Institute. For both hiPSC lines somatic cells were
transduced with the excisable STEMCCA-loxP lentivirus
encoding human Oct4, Sox2, Klf4, and c-Myc (Millipore)
(Sommer et al., 2009). The same donors' fibroblasts or a
different healthy donors' human PBMC were used in parallel
for ESI–MSe analysis. hiPSC derivation, culture, and their
quality control, as well as the list of hiPSC lines used in the
validation of a protein marker panel are described in the
Supplementary information. The purity of both hiPSC lines
was checked by immunocytochemistry, and it was shown
that more than 90% of cells are expressing pluripotency
markers (Supplementary Fig. 1).
The study was performed under NIAID IRB approved
protocols 05-I-0213, 94-I-0073, and 09-I-0133, NINDS IRB
approved protocol 00-N-0043, and FDA Research Involving
Human Subjects Committee (RIHSC) approved protocol #s
13-052B and 13-053B.
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The preparation of samples for MS analysis is described in the
Supplementary information. 20 μg of digested protein (2 μl
of each sample) was loaded and analyzed by a reverse phase
(RP) nanoACQUITY™ ultrapressure liquid chromatography
(UPLC) and Synapt G2 or Xevo-qTOF mass spectrometers
operating in a data-independent (MSe) mode (Waters). Three
technical replicates (sample injections) were done for each
run in total. The HDMSe (Synapt G2) or MSe (Xevo-qTOF) data
were processed and protein absolute label-free quantifica-
tion (Silva et al., 2005, 2006) was performed using Protein
Lynx Global Server version 2.5 (Waters). A maximum false
discovery rate of 2% was allowed. All protein hits that were
identified with a confidence of N95% were included in the
quantitative analysis.Label-free quantification, quantitative comparison
and IPA analysis
Each protein was identified by at least three peptides that
are required for quantification. Proteins identified in at
least two out of three technical replicates were used for
comparison. For quantitative comparison, we used combi-
nation criteria that consider both data variability and a fold
change cutoff. Proteins for which the quantity didn't change
by more than 30% (CV b 30%) in at least two out of three
technical replicas, were considered. The “differentially
expressed” proteins are proteins for which the expression
level changed by≥1.5 fold between the compared cell lines,
or are uniquely expressed (identified in at least two out of
three technical replicas and in only one of the two compared
cell lines). A list of UniProt ID numbers of differentially
expressed proteins for a given cell line was submitted to
Ingenuity Pathway Analysis (IPA) (Ingenuity Systems) to
determine the biological processes and canonical pathways
affected by these proteins.MALDI-MS analysis
MALDI-MS analysis was performed as described previously
(Mindaye et al., 2013a, 2013b) (see brief description in the
Supplementary information). Three technical replicates
were performed for each sample.Western blot analysis
Protein samples were prepared using the same protocol
as for MS analysis. Protein content was measured using
BCA Protein Assay kit (Pierce) and equal amount of total
protein (15–20 μg/well) from each sample was resolved
by SDS-PAGE, transferred to the nitrocellulose mem-
brane using iBlot system (Life Technologies) and blotted
with different primary antibodies (ABs) and IRDye
secondary ABs (Li-Cor) using a standard protocol. See
the Supplementary information for the list of antibodies.
Odyssey Imaging System (Li-Cor) was used for signal
detection.Results
Qualitative global proteome analysis of one hESC line (H9),
two hiPSC lines (SB5-MP1 and iNC-01), and their parental
primary cells (fibroblasts and PBMC) was performed by
both MS techniques, ESI–MSe and MALDI TOF/TOF (latter
data are described in a separate section). Quantitative
global proteome analysis of these hESC and hiPSC lines was
performed by ESI–MSe. Two biological replicates for each
cell line (one at the earlier and one at the later cell culture
passage for hESC and hiPSCs) and three technical replicates
were analyzed by both MS techniques. The number of
proteins identified by ESI–MSe and selected for quantitative
comparison in each cell line is shown in Table 1. In the table
the earlier cell culture passages of pluripotent cell lines
(hESC-H9-P.34, SB5-MP1-P.22, iNC-01-P.36) and the 1st
biological replicate of fibroblasts and PBMC were analyzed
by Xevo-qTOF mass spectrometer (in MSe mode). The later
cell culture passages of pluripotent cell lines (hESC-H9-P.48,
SB5-MP1-P.28, iNC-01-P.53) and the 2nd biological replicate
of fibroblasts and PBMC were analyzed by SYNAPT G2 High
Definition Mass Spectrometer (HDMS) (in HDMSe mode, which
allows an additional, fourth dimension of peptide separa-
tion). This resulted in a higher number of proteins identified
and quantified in the 2nd biological replicate for most of the
cell lines (Table 1). We performed a pairwise comparison of
a protein expression level among the different cell lines for
each biological replicate separately, and then obtained a list
of commonly differentially expressed proteins in both
analyzed passages. The cut off for the expression level
change between the compared cell lines was set up as ≥1.5
fold to avoid missing potentially valuable proteins.
Comparative proteomics of hiPSCs and their paren-
tal somatic cells
The list of proteins differentially expressed between hiPSC
derived from fibroblasts (SB5-MP1) and fibroblasts is shown
in Supplementary Table 1 (a–f). Eighty nine (89) proteins
were commonly down-regulated and 424 proteins were
commonly up-regulated in hiPSC (SB5-MP1) compared to
fibroblasts in both earlier and later passages (P22 and P28)
(Table 1; Supplementary Table 1(e–f)). The list of proteins
differentially expressed between hiPSC derived from CD34+
hematopoietic cells (iNC-01) and PBMC is shown in Supple-
mentary Table 2 (a–f). Two hundred forty two (242) proteins
were commonly down-regulated and 540 proteins were
up-regulated in iNC-01 compared to PBMC respectively in
both biological replicates (P36 and P53) (Table 1; Supple-
mentary Table 2).
The lists of differentially expressed proteins for both hiPSC
lines were analyzed using IPA. The results are summarized in
Fig. 1A (SB5-MP1) and Supplementary Fig. 2 (iNC-01). Biological
processes up-regulated exclusively in hiPSC or in somatic
cells are shown in red. The top biological functions affected
by up-regulated proteins in both hiPSCs included: RNA
post-transcriptional modification, protein synthesis, gene
expression, cellular growth and proliferation, DNA replica-
tion, recombination, and repair, which are characteristics
of highly proliferating pluripotent stem cells. In contrast,
cellular movement, cell morphology, cellular assembly and
Table 1 Number of proteins (protein groups) identified and quantified in five different cell lines (hESC (H9), hiPSCs (SB5-MP1 and
iNC-01), fibroblasts, and PBMC) by ESI-MSe.
Cell line hESC–H9 hiPSC (fibro)– 
SB5–MP1
Fibroblasts hiPSC 
(CD34+cells) 
– iNC–01
PBMC
Passage P34 P48 P22 P28 N/A P36 P53 N/A
# of proteins 
identifieda
1817 1624 954 1981 642 1660 1189 1522 939 1021
# of proteins 
quantifiedb
1690 1439 848 1785 547 1464 1074 1345 775 869
# of proteins 
selected for 
quantitative 
comparisonc
1510 1185 736 1448 320 1266 895 1104 587 691
# of proteins 
up–regulatedd
62 in H9 vs. SB5–
MP1;
149 in H9 vs. 
iNC–01
429 in SB5–MP1 vs. fibroblasts 540 in iNC–01 vs. PBMC
# of proteins 
down–
regulatedd
50 in H9 vs. SB5–
MP1;
134 in H9 vs. 
iNC–01
89 in SB5–MP1 vs. fibroblasts 242 in iNC–01 vs. PBMC
aNumber of proteins confidently identified in at least two out of three technical replicates (sample injections).
bNumber of proteins depicted in the first row and identified by at least three peptides that are required for quantification.
cNumber of proteins depicted in the second row with CV ≤ 30% between at least two out of three technical replicates.
dProteins differentially expressed in both biological replicates (overlapped between both passages); N/A – not applicable; number of
proteins used for quantitative comparison is shown in red.
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and survival, cell-to-cell signaling, etc. were top biological
functions up-regulated in fibroblasts and PBMC. Overall,
significant difference in the proteomic profiles was ob-
served between somatic cells and hiPSCs.Comparative proteomics of hESC (H9) and hiPSCs
The list of proteins differentially expressed between H9 and
SB5-MP1 is shown in Supplementary Table 3 (a–f) and between
H9 and iNC-01 — in Supplementary Table 4 (a–f). The number
of proteins up- and down-regulated in SB5-MP1 compared
to H9 in both analyzed passages was 50 and 62, respectively
(Table 1). The number of proteins up- and down-regulated
in iNC-01 compared to H9 were 134 and 149, respectively
(Table 1).IPA analysis revealed that there are only subtle differences
between the functional groups affected by the differentially
expressed proteins between hiPSCs and hESC (Supplementary
Figs. 3 and 4). Such biological functions as cellular assembly
and organization, cellular functions andmaintenance, cellular
growth and proliferation, protein synthesis and trafficking,
cell-to-cell signaling, amino acid and lipid metabolism,
cell cycle, etc. were similarly affected in hiPSC (SB5-MP1 or
iNC-01) and hESC. At the same time energy production was
up-regulated in both hiPSCs; protein folding and cellular
response to therapeutics were up-regulated only in iNC-01 vs.
H9; RNA trafficking, protein folding, protein degradation were
up-regulated in H9 vs. SB5-MP1; cell signaling, RNA damage and
repair, and free radical scavenging were up-regulated only in
H9 vs. iNC-01.
When we analyzed the list of the main Ingenuity Canonical
Pathways differentially regulated between hiPSCs and hESC
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signaling by Rho family GTPases, integrin signaling, and actin
cytoskeleton signaling, were up-regulated in H9 cells; and EIF2
signaling, regulation of eIF4 and p70S6K signaling and mTOR
(p-value b 0.00001) were up-regulated in both hiPSCs com-
pared to H9 cells.
Proteomes of hiPSC lines of different somatic origins
are more similar to each other than to proteome
of hESC
The list of proteins differentially expressed between iNC-01 and
SB5-MP1 is shown in Supplementary Table 5 (a–f). Combining
proteomic analyses done at the earlier and later passages, 36
and 49 proteins were found to be up- and down-regulated in
SB5-MP1 vs. iNC-01, respectively. This list was analyzed
using IPA: virtually the same biological functions, mainly
related to stem cell maintenance, were affected in both
hiPSCs (Supplementary Fig. 5). However, post-translation
modification and RNA damage and repair were up-regulated
solely in SB5-MP1, and molecular transport, RNA trafficking,
energy production, vitamin and mineral metabolism and
carbohydrate metabolism were up-regulated only in iNC-01.
We found that no particular canonical pathway was differen-
tially regulated in any of hiPSC lines.
Quantitative comparison of proteomes of hiPSCs,
hESC and somatic cells confirmed previously described
and revealed novel candidates for pluripotency
markers
A comparison of proteins commonly up-regulated in both hiPSCs
vs. their parental somatic cells is summarized in Supplementary
Table 6 (a& b). The table lists 982 proteins up-regulated in both
hiPSCs in at least one biological replicate (b) and 257 proteins
(26%) up-regulated in both hiPSCs in both biological replicates
(a). Among these 257 proteins 221 were also up-regulated in
hESC (H9) compared to primary somatic cells.
To observe global changes that occurred in hiPSC upon
reprogramming we analyzed the combined list of proteins
up-regulated in both hiPSCs (982 in total) using IPA and
identified 25 functional networks (score 26–50) with 24–34
focus molecules contained in each network (data not shown).
The top 30 Ingenuity canonical pathways involving proteins
up-regulated in both hiPSCs (p-value b 0.01) are presented in
Fig. 1B. Among the most statistically significant up-regulated
canonical pathways with more than 15molecules involved and
p-value b 0.000001 were: EIF2 signaling, regulation of eIF4
and p70S6K signaling, mTOR, the protein ubiquitination
pathway, RAN signaling, and tRNA charging. In general, 6 to
90 proteins were identified to be involved in the top 30
up-regulated canonical pathways (Supplementary Table 7).
The subcellular localization of the 982 proteins is displayed in
Fig. 1C. 39% of these proteins are located in cytoplasm, 31% in
nucleus, and only 11% are membrane proteins, of which 44%
are cellular membrane proteins. Among them were EPCAM
(CD326), a well-known ESC marker (Chen et al., 2011), and
several other proteins, which have not been used previously
for hiPSC selection: 4 F2 (CD98), TFR1 (CD71), AT1B3 (CD298),
and Basigin (CD147). They can be considered as potential
candidates for hiPSC surface markers.To determine how well the results of this study compare to
the published literature, we compiled a list of previously
described pluripotency markers and stemness maintenance
regulators and checked whether they were identified in this
study and by which MS technique (ESI MS, MALDI MS or both). It
has been previously shown that ESI and MALDI are comple-
mentary ionization techniques due to being biased to different
types of tryptic peptides, ESI to Lys-ending, and MALDI to
Arg-ending (Stapels and Barofsky, 2004; Heller et al., 2003;
Bodnar et al., 2003). Supplementary Table 8 summarizes the
gene expression data, the proteomics data, and the functional
studies data previously obtained for hiPSC and hESC. We found
that 23 previously described markers were identified
exclusively by ESI-MSe (Table 2). In addition, 28 markers
were identified by both MS techniques: MALDI-TOF/TOF and
ESI–MSe (Table 2). In our opinion, the best case scenario is
to use both ionization techniques since they complement
each other. In Table 2, for example, such hiPSC marker as
PODXL (TRA-1-60) was identified by ESI–MSe exclusively; SALL4
and DNMT3B were identified by both ionization techniques. In
silico digestion of these proteins with peptide range of 950 to
4000 m/z (data not shown) yields peptides ending mostly by
lysine (K ending peptides/R ending peptides ratios are 1.8
(PODXL), 1.4 (DNMT3B) and 1.6 (SALL4)).
From the list of markers identified by ESI–MSe in our
study, 21 proteins were found to be up-regulated in both
hiPSCs compared to somatic cells (shown in red in Table 2
and in Supplementary Table 6 (a & b)). We confirmed
ESI-MSe quantification (Fig. 2A) for seven of these proteins
by Western blot analysis (Fig. 2B).
In spite of using two complimentary MS techniques (ESI and
MALDI) we could not reliably identify expression of c-Myc,
FGF4, Klf4 and Oct3/4 (POU5F1) in our cells. Previous mass
spectrometry-based studies also failed to identify c-Myc, FGF4,
and Klf4, but identified Oct3/4 (POU5F1) (Munoz et al., 2011).
Western blot analysis of 5 cell lines targeting these proteins
(Fig. 2C) revealed that they all are expressed in hESC and both
hiPSCs. Expression of FGF4 (also expressed in fibroblasts)
and Klf4 was also detected in PBMC. The expression of Klf4
in human PBMC has been shown previously by Western blot
detection (Liu et al., 2012), but the expression of FGF4 in
PBMC has not been reported. In an effort to understand why
we and others could not reliably identify these four well
known markers of pluripotency we analyzed their amino
acid sequences from the point of view of compatibility for
MS-based proteomics. Supplementary Table 9 summarizes
this information for the four problematical pluripotency
markers and some selected proteins reliably identified by
our approach. As an example, c-Myc is a midsize protein
(48.8 kDa) and contains 25 Lys and 26 Arg. However, these
amino acids are not evenly distributed along the c-Myc
sequence. Taking into account a peptide mass range of 750–
3000 Da (optimum mass range for MS identification) and
assuming complete tryptic digestion of c-Myc, we could
generate a maximum of 13 peptides covering 37% of the
protein sequence. Further, a number of Lys residues (7) are
acetylated which renders them unsuitable for digestion.
Thus, a trypsin digest will not generate a sufficient number
of tryptic peptides with sizes optimal for MS detection,
unless one chooses to use 1 tryptic peptide for identification
purposes. Correspondingly, some of these four pluripotency
markers were identified in our study but did not pass the
Figure 1 Characteristics of proteins up- or down-regulated in hiPSCs compared to somatic cells. (A): Example of Ingenuity Pathway
Analysis results: biological processes affected by the proteins up- or down-regulated in SB5-MP1 vs. fibroblasts. The p-value cut-off is
b0.05 (N1.3 in − log10). Biological processes affected by up-regulated proteins exclusively in hiPSC or in somatic cells are shown in
red. (B): Top Ingenuity canonical pathways up-regulated in both hiPSCs compared to primary parental cells (p-value b 0.01). (C):
Subcellular localization of the proteins up-regulated in both hiPSCs vs. primary cells.
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329Protein marker panel for characterization of human iPSCfiltering criteria, such as identification scores, overall
probability or FDR.
Based on the data obtained, we selected 12 proteins,
including one cell surface marker (CD147), not used previously
as pluripotency markers but consistently up-regulated in our
experiments in early and late passage cells of both hiPSC lines,
for confirmation by Western blot analysis. During the validation
of ESI-MSe quantification we initially performed Western blot
analysis for the identified proteins on the early and late
passage cells separately and compared the results to the
quantification done for each biological replicate separately
(data not shown). Having similar results between cell passages,
here we present the validation of quantification of these 12
selected hiPSC markers by ESI-MSe (TOF) (done on the 1st
biological replicate) with Western blot (Figs. 3A and B). The list
included: HSP90-beta, HSPA8, Peroxiredoxin1, Prohibitin2,
Stathmin1, XRCC5 (Ku80), MCM4, TIF1-beta (TRIM28), Basigin
(CD147), Cathepsin D, IDH1 and ACACA (blue bold font in
Supplementary Table 6). By looking at the Supplementary
Table 6 and comparing the quantity of these proteins,
measured by ESI-MSe, between earlier and later passages
(biological replicates 1 and 2), it becomes obvious that
there is no evidence for coordinately higher expression of
these proposed hiPSC markers (blue bold) or previously
known pluripotency markers (red bold) in one or the other
passage. In other words, we did not observe any major
differences between different passages of the same hiPSC
line. All selected proteins were confirmed to be up-regulated
in hiPSC and hESC compared to somatic cells.
We also looked at the proteins that were dramatically
down-regulated upon reprogramming and could serve as
“contrasting hiPSC markers” (Supplementary Table 10 (a–d)).
We selected four of them for confirmation by Western blot
analysis (Figs. 3C and D, highlighted in blue bold font in
Supplementary Table 10). They are Gelsolin, Calpain 1 (large
subunit), LCP1 (Plastin-2) (all highly expressed in PBMC), and
Annexin A2 (highly expressed in fibroblasts). For all four
proteins quantification data by ESI-MSe (TOF) (Fig. 3C) corre-
lated well with detection by Western blot (Fig. 3D).
In summary, comparative quantification between hiPSCs
and somatic cells by ESI-MSe allowed confirmation of 21
previously known pluripotency markers and selection of 12
novel hESC/hiPSC protein markers and 4 somatic cell (“con-
trasting”) markers.Global qualitative proteome characterization of
hESC and hiPSCs of different somatic origins by
MALDI MS
Since ESI and MALDI have different biases toward Arg- and
Lys-ending tryptic peptides we performed global qualitative
proteome characterization of these cell lines with MALDI-TOF/
TOF to expand the proteome coverage of hESC and hiPSCs. All
three stem cell lines were analyzed at earlier and later
passages (H9: P34 and P48, SB5-MP1: P22 and P28, iNC-01:
P36 and P53). The goal of this study was to identify common
hiPSC/hESC markers that would be largely independent on
number of passages; therefore we did not compare earlier and
later passages between each other, but rather analyzed the
data combined from both passages. For proteins confidently
identified by MALDI MS, the Mascot score, % of the proteinsequence coverage, number of total peptides and number of
unique peptides used for identification are reported in
Supplementary Table 11. All proteins (protein groups) identi-
fied in two different passages of each analyzed stem cell line
are shown in Supplementary Table 11-a, and proteins identified
in all three stem cell lines are shown in Supplementary Table
11-b; proteins that were confirmed by Western blot analysis
are highlighted in red.
Thenwe compared the combined lists of proteins identified
by MALDI MS and by ESI-MSe between each other for each of
the cell line (Fig. 4A). We found that the number of proteins
identified by each of the MS techniques exclusively (ranging
from 710 to 3420 — by MALDI MS and from 926 to 1664 — by
ESI-MSe) is much higher than the number of proteins identified
by both MS techniques (ranging from 315 to 696) (Fig. 4A).
Overall from 18 to 67% of total number of proteins in each cell
line was identified uniquely either by MALDI MS or ESI-MSe, and
only 12–16% of proteins were identified by both MS tech-
niques. Similar data have been previously reported by our
laboratory for humanmesenchymal stem cells (Mindaye et al.,
2013a). Therefore, the use of both ionization techniques
allowed us to increase the proteome coverage significantly.
In fact, 46 previously described pluripotency markers were
identified exclusively by MALDI MS (Table 2, Supplementary
Table 8). These include widely used hiPSC/hESC markers:
BMP2, BUB1, FGFR2, Sox2, TERT, and TGFBR1. 126 proteins in
total were commonly identified in all three pluripotent stem
cell lines exclusively by MALDI MS (Fig. 4B; Supplementary
Table 10-b). Several proteins, with functions arguably related
to the establishment of the pluripotency or stemness
maintenance, were confirmed by Western blot. Six proteins
were confirmed to be up-regulated in hESC and hiPSCs
compared to primary cells (Fig. 4C). These include: previously
described EHMT2 (Sridharan et al., 2013) and 5 novel
markers: TAOK1, CACNA1A, CUX2, STAG2, and PASK.Protein markers panel developed using two MS
techniques was further confirmed in eight (8) addi-
tional hiPSC lines and one additional hiPSC passage
Based on the results of the global quantitative proteome
comparison of the five cell lines bymass spectrometry followed
by the confirmation using Western blot we selected 20
candidates for the protein markers of hESC/hiPSC, as well as
2 “contrasting” (somatic cell) markers and combined them into
a panel. Prior to further validation of the panel we looked at
the expression of these 22 proteins in normal human tissues and
cancer tissues. The data were obtained from “The Human
Protein Atlas” (www.proteinatlas.org) and summarized in
Supplementary Table 12: tissue specificity in 76 to 83 different
human cell types, cancer tissue staining summary in 20 types of
cancer, the main subcellular localization of each protein and
summary of expression are presented. Most of the selected
proteins are expressed in the majority of the normal tissues,
however, some of the proteins; specifically, IDH1, HSPA8, GSN,
EHMT2, CACNA1A and APOE are expressed only in certain types
of tissue (Supplementary Table 12). As a matter of comparison,
a well-known transcription factor Oct3/4 (POU5F1), which is
essential for embryonic stem cell pluripotency, shows low to
moderate expressions in 81 out of 81 analyzed cell types, with a
strong immunoreactivity in Glial cells, heart and skeletal
Table 2 Previously described pluripotency markers (gene names) identified in our study in three stem cell lines: hESC (H9) and
hiPSCs (SB5-MP1 and iNC-01) by ESI-MSe, MALDI-TOF/TOF or both. Markers shown in red were up-regulated in both hiPSCs vs.
parental somatic cells by ESI-MSe quantification.
Identified exclusively by ESI–
MSe
Identified exclusively by MALDI–
TOF/TOF
Identified by both MS 
techniques
AIBP SMAD4 ADCY2 FGFR2 SOX15 ACTC1 RIF1
APOE STAT3 APC FINC TBX3 ACTG2 SALL4
APOO VSNL1 BBS9 GAB1 TERT ALPL SERPIN B9
BRIX BCL9 GPC6 TGFBR1 AXA2L SFN
CDK1 BCL9L GSK3A TP53 CALR SMAD3
CTNNB1 BMP2 JAK3 WWP2 CXADR TFR1
GNAS2 BUB1 LAD1 DNMT3B TPM1
HP1–beta CHD1 MEF2A DPPA4 TUBB3
GRB2 CHD7 NR2F6 FGFR4
KRAS CLU NRK FUBP3
MANF CNOT3 PDFGA GMFB
MAPK2K2 CNTNAP2 PIK3C2A GNAS
MFGM COIA1 PIK3C2B GPC4
MIF DAG1 PIK3R2 HDAC2
NEFM DCX PXDN HDGF
NEST DMD RARA IGF2BP1 (IMP1)
P3H1 EHMT1 RB1 LAMC1
PODXL (Tra–1–60) EHMT2 S1PR1 LIN28
RRAS2 EP300 SMAD2 MAPK1
SHC1 FAT3 SOX2 PRDX4
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Figure 2 Validation of quantification by ESI-MSe of the previously described pluripotency markers by Western blot. (A): Selected
previously described markers of pluripotency quantified by ESI-MSe (TOF). Absolute quantity (fmol/10 μg) in each cell line is shown in
the chart. The absolute quantity of GAPDH in each cell line estimated by ESI-MSe was found to be unchanged in all 5 cell lines. (B):
Western blot analysis of three pluripotent (hESC-H9, SB5-MP1 and iNC-01) and two parental primary (PBMC and fibroblasts) cell lines.
Protein quantity was normalized against GAPDH. * denotes markers also detected by MALDI-TOF/TOF. (C): Known markers of
pluripotency not identified by any of MS techniques in this study but detected by Western blot.
331Protein marker panel for characterization of human iPSCmuscles, and low to moderate staining in 94% of the cancers
(www.proteinatlas.org).
Finally, we tested the proposed protein marker panel in 9
hiPSC lines of different somatic origins, derived by different
reprogramming methods in different laboratories. They includ-
ed three CD34+ cell-derived hiPSC lines: iNC-06s-2E-P16
(passage 16) reprogrammed using non-integrating Sendai virus,
iNC-01 at an even earlier passage — P31 and iM6-1-5-P18
both reprogrammed using STEMCCA-loxP lentivirus, which was
subsequently excised; four adult fibroblasts-derived hiPSC lines
iM6-3-2-P19, NC1-P38, NC8-P8, and 80-4-P20, all reprogrammed
using STEMCCA-loxP lentivirus; one human umbilical vein
endothelial cell (HUVEC)-derived hiPSC line NC3-P16 also
reprogrammed using STEMCCA-loxP lentivirus; and one fetal
fibroblast-derived hiPSC line iPS(IMR90)-1-P30, reprogrammed
using four non-excisable lentiviruses (Yu et al., 2007). First we
checked the expression of 5 previously described hESC/hiPSC
markers in these hiPSC lines (Fig. 5A), including widely used
Lin28 and FUBP3, as well as the markers that have been
previously described in a literature and confirmed by MS
analysis and Western blot in our study (APOE, EHMT2, and
IMP1). All markers were confirmed to be up-regulated in all 9
hiPSC lines compared to fibroblasts. Then we evaluated our
newly developed panel of the markers selected based on theproteomic analysis by ESI-MSe (Fig. 5B) and MALDI-TOF/TOF
(Fig. 5C). All 17 selected hiPSC markers were confirmed to be
highly expressed in all 9 hiPSC lines but not in fibroblasts.
Finally, we confirmed that two previously selected “contrast-
ing” markers of hiPSC (Annexin A2 and Gelsolin) were
down-regulated upon reprogramming in all 9 hiPSC lines but
were expressed in fibroblasts or PBMC.
In summary, all the proteins selected as candidates for
the protein marker panel designed for hiPSC characteriza-
tion (listed in Supplementary Table 12) were confirmed to be
differentially expressed in hiPSCs (10 unique hiPSC lines
were tested in total) compared to two somatic cell types
(fibroblasts and PBMC) and therefore are promising candi-
dates for the panel.Discussion
The establishment of an appropriate quality control assays
for hiPSC would be an important step in advancing their
clinical translation. Our goal in this study was two-fold; on
one hand we wanted to use proteomics to characterize the
cellular state and biological functions activated in induced
pluripotent stem cells, on the other hand to build a database
Figure 3 Candidates to hESC/hiPSC markers found in this study by comparative quantification of five cell lines using ESI-MSe. (A):
Quantification of 12 candidates to markers by ESI-MSe (TOF). Absolute quantity (fmol/10 μg) in each cell line is shown in the chart.
Protein quantity was normalized against GAPDH. Absolute quantity for GAPDH measured by ESI-MSe was the same as in Fig. 2. (B):
Western blot detection of the 12 candidates to markers in three pluripotent (hESC-H9, SB5-MP1 and iNC-01) and two parental primary
(PBMC and fibroblasts) cell lines. Protein quantity was normalized against GAPDH. (C): Quantification of 4 candidates to “contrasting”
markers by ESI-MSe (TOF). (D): Western blot detection of the candidates to “contrasting”markers. * denotes markers also detected by
MALDI-TOF/TOF.
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Figure 4 Results of MALDI-TOF/TOF analysis of three pluripotent stem cell lines: hESC-H9, SB5-MP1 and iNC-01. (A): Number of
proteins detected by MALDI-TOF/TOF exclusively, by ESI-MSe exclusively or by both techniques in each cell line in at least one out of
two biological experiments. (B): Number of common proteins between three cell lines identified in at least one out of two biological
experiments exclusively by MALDI-TOF/TOF (not detected by ESI-MSe). (C): One previously described (*) and 5 novel markers of hESC/
hiPSC detected by MALDI-TOF/TOF exclusively were validated by Western blot analysis in three pluripotent and two parental primary
(PBMC and fibroblasts) cell lines. Protein quantity was normalized against GAPDH.
333Protein marker panel for characterization of human iPSCof protein markers for characterization of hiPSC as a cell
therapy product precursor, which could be further differen-
tiated into any cell lineage.
When the proteomes of both hiPSCs were quantitatively
compared with the proteomes of their parental primary cells
~420 to 540 up- and ~90 to 240 down-regulated proteins
were found in both hiPSCs in two biological replicates.
Biological functions affected by the differentially expressed
proteins in both hiPSCs overlapped significantly. Coordinat-
ed up-regulation of expression of the whole set of large
and small subunit ribosomal proteins, chaperons (HSP90 and
HSP70) and chaperonins (CCT2, CCT7, TEBP), hnRNPs
(heterogeneous nuclear ribonucleoproteins), t-RNA synthe-
tases, and such transcriptional and splicing factors as
TARDBP (TAR DNA binding protein), YBX1 (Y box binding
protein), FUS (RNA-binding protein FUS) was observed in
both hiPSCs compared to somatic cells.
Among the top 30 Ingenuity Canonical Pathways up-
regulated in both hiPSCs (p-value b 0.01) the following were
found to be consistent with the data in two recent proteomics
studies performed in hiPSC: EIF2 signaling, regulation of eIF4
and p70S6K signaling, protein ubiquitination, purine nucleotides
de novo biosynthesis, NRF2-mediated oxidative stress response
(Folmes et al., 2013); mismatch repair in eukaryotes, DNA
double-strand break repair by non-homologous end joining,and cell cycle control of chromosomal replication (Sudhir et
al., 2013). In line with the above studies, we have revealed
up-regulation of the protein complexes involved in: RNA
splicing and spliceosome formation (snRPs, hnRNP70, CDC5L);
cell cycle control of chromosomal replication (MCM complex);
mismatch repair and DNA double-stranded break repair by
homologous recombination (MRE11A, BASC); estrogen and
glucocorticoid receptor signaling (POLRs); mRNA surveillance
(EXOSC).
In contrast to previously published data (Folmes et al.,
2013; Menendez et al., 2011) we found that protein complexes
involved in oxidative phosphorylation (OXPHOS), such as ATP
synthase, NADH dehydrogenase (Complex I), Cytochrome b-c1,
Cytochrome C, Cytochrome b5, H+-transporting two-sector
ATPase, as well as mTOR signaling (54 molecules involved in
total) were up-regulated in both hiPSCs (Supplementary Table
7). At the same time, among the markers of the transition to
glycolytic metabolism we found only four up-regulated
proteins: ENO2, TKT, ALDOB and PGAM1. Therefore, observa-
tions made for our hiPSC lines did not agree with previously
described reprogramming-associated induction of glycolysis
and down-regulation of mitochondrial reserve capacity and
ATP turnover (Folmes et al., 2013; Menendez et al., 2011). This
could be due to several factors, including differences between
data obtained on the early (right after reprogramming) (Folmes
Figure 5 Qualification of the panel of 22 previously described and novel hESC/hiPSC protein markers and two opposed (somatic
cell) markers in 9 hiPSC lines, primary fibroblasts and PBMC by Western blot. (A): Well-known markers (*) and proteins that were
previously described in a literature as possible hESC/hiPSC markers. (B): Novel hiPSC/hESC markers found in this study by ESI-MSe
quantification. (C): Novel markers detected in hESC/hiPSC in this study exclusively by MALDI-TOF/TOF. (D): “Contrasting” markers
found in this study by ESI-MSe quantification. Nine hiPSC lines used in analysis (origin): 1 — iNC-06s-2E — P16 (CD34+), 2 — iNC-01 — P31
(CD34+), 3 — iM6-3-2 — P19 (adult fibroblasts), 4 — iM6-1-5 — P18 (CD34+), 5 — iPS(IMR90)-1 — P30 (fetal fibroblasts), 6 — NC1-P38
(adult fibroblasts), 7 — NC3-P16 (human umbilical vein endothelial cells (HUVECs)), 8 — NC8-P8 (adult fibroblasts), 9 — 80-4-P20
(adult fibroblasts).
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as well as between hiPSCs of different somatic origins.
Importantly, it has been recently demonstrated that although
the energy production of hiPSC favors glycolysis over OXPHOS,
mitochondria in hiPSC still possess functional respiratory
complexes (Zhang et al., 2011). The decoupling of glycolysis
from OXPHOS was suggested to be regulated by several
factors, including mitochondrial uncoupling protein 2 (UCP2)
(Zhang et al., 2011). In addition, there are studies confirming
that mitochondrial dynamics and maintenance of proper
mitochondrial network integrity are crucial for the mainte-
nance of pluripotency (Xu et al., 2013). Nevertheless, pivotal
lipogenic enzymes acetyl-CoA carboxylase (ACACA) and fatty
acid synthase (FASN) (involved in lipogenic switch) were
up-regulated in our study in both hiPSCs, in line with a recent
publication (Vazquez-Martin et al., 2013).
Variations on the level of genomic DNA between different
pluripotent stem cells, as well as transcriptional and epige-
netic profile differences can contribute to their pluripotency,
stability and differentiation potential (Bock et al., 2011;
Sugawara et al., 2012; Ma et al., 2014). Recent genome-wideanalysis of genetically matched sets of hiPSC, hESC, and
somatic cell nuclear transfer (NT) ESC has revealed that both
NT-ESC and hiPSC contained a number of de novo copy
variations; exome sequencing has demonstrated that hiPSC
carry, on average, six non-synonymous point mutations per
line (Ma et al., 2014). In addition, hiPSC retained residual DNA
methylation patterns typical of parental cells (Ma et al.,
2014). On the other hand, proteomic studies have shown that
hiPSC proteome is almost indistinguishable from that of hESC
(Munoz et al., 2011; Phanstiel et al., 2011; Kim et al., 2012).
From about 2500 proteins confidently quantified in two
different studies only 58 and 293 proteins were differentially
expressed between hiPSC and hESC in 2 fold or less (Munoz et
al., 2011; Phanstiel et al., 2011). Moreover, when the data
sets from these two studies were compared, only three
proteins were found to be consistently up-regulated in
hESC vs. hiPSC: CRABP1, AK3 and SLC2A1 (Benevento and
Munoz, 2012). Therefore, minor genomic variations or
epigenetic profiles difference between different hiPSC/
hESC lines may not be observed in the global proteome
comparison.
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hESC revealed only ~50–150 proteins up- or down-regulated in
both hiPSCs compared to H9 cells. CRABP1 and AK3 were also
down-regulated in hiPSCs vs hESC (Supplementary Tables 3
and 4). Different proteins within the same functional network
were either up- or down-regulated in hiPSCs compared to
hESC, and no coordinated changes were found within any
network. However, it is of interest that energy production was
up-regulated in both hiPSCs vs. hESC. There were a number of
canonical pathways (p-value b 0.00001) up-regulated in both
hiPSCs in comparison to H9 cells, such as EIF2 signaling,
regulation of eIF4 and p70S6K signaling and mTOR.
A smaller number of differentially expressed proteins
between hiPSCs of different somatic origins, and less signifi-
cant p-value associated with differentially regulated biological
processes between them, than between hiPSCs and hESC, were
observed. Besides, no statistically significant differentially
regulated canonical pathways between hiPSCs were found.
Based on that, we conclude that analyzed hiPSC lines are more
similar to each other than to hESC. Importantly, analogous
conclusion was made previously based on genome-wide
expression data in mouse and human iPSC (Chin et al., 2009).
48 previously known pluripotency markers were identified
by ESI-MSe in hiPSCs, from which 21 proteins were found to be
up-regulated (≥1.5-fold) in both hiPSCs compared to somatic
cells, and 7 of these proteins were confirmed by Western blot
analysis in this study. Quantification of 12 selected novel
potential pluripotency markers candidates (including one
cell surface marker (Basigin, CD147)) was confirmed by
Western blot analysis. Some of these proteins have been
previously studied in a context of the stemness maintenance
and regulation of the pluripotency. Over-expression in hESC or
hiPSC of APOE, IGF2BP1 (Ghosh et al., 2010; Sarkar et al.,
2012), HSPA8 (Son et al., 2005), isocitrate dehydrogenase 1
(IDH1) and Peroxiredoxin-1 (Prxd 1) (Roche et al., 2013)
was demonstrated previously by gene expression or proteomic
analysis. Heat shock protein 90 kDa beta (HSP90B1) has
been shown to regulate pluripotency in mouse ESC and
potentially regulate the folding of Oct4 and Nanog as the client
proteins (Bradley et al., 2012). ACACA, has been found to be
up-regulated in mouse iPSC (Vazquez-Martin et al., 2013); and
tripartite motif containing 28, TRIM28 (TIF1B), has been shown
to regulate the transcriptional dynamics and retroviral silenc-
ing in hESC (Wolf and Goff, 2007; Seki et al., 2010; Rowe et al.,
2013).
It is well established that two different ionization tech-
niques, MALDI and ESI, have different biases toward Arg- and
Lys-ending tryptic peptides and thus complement each other
(Stapels and Barofsky, 2004; Heller et al., 2003; Bodnar et al.,
2003). Our MALDI MS/MS analysis revealed 46 additional
previously known pluripotency markers in hiPSCs, hESC or
both. From ~120 proteins commonly expressed in all three
pluripotent cell lines identified exclusively by MALDI MS/MS we
selected six proteins that were confirmed to be up-regulated in
hESC and hiPSCs vs. primary cells by Western blot. They are:
serine/threonine-protein kinase TAOK1, voltage-dependent P/
Q-type calcium channel subunit alpha-1A (CACNA1A), homeo-
box protein cut-like 2 (CUX2), Cohesin subunit SA-2 (STAG2),
PAS domain-containing serine/threonine-protein kinase (PASK)
and EHMT2 (G9a methyltransferase). EHMT2 was previously
described to be involved in regulation of the global histone
methylation levels in hiPSC (Folmes et al., 2013). TAOK1has been shown to be involved in p38/MAPK14 stress-activated
MAPK cascade, DNA damage response and regulation of
cytoskeleton stability (Raman et al., 2007; Westhorpe et al.,
2010). It has also been reported to be highly expressed in the
testis, and to a lower extent in the brain, placenta, colon and
skeletal muscle (Yustein et al., 2003). PASK is another serine/
threonine-protein kinase involved in energy homeostasis and
protein translation; it is ubiquitously expressed, with slightly
higher expression in the brain, prostate and testis (Schlafli et
al., 2009). Interestingly, CACNA1A has been previously shown
to be brain specific; mainly found in the cerebellum, cerebral
cortex, thalamus and hypothalamus (Oguro-Okano et al.,
1992). The functions of CUX2 have just recently been described
as a likely transcription factor, which binds to DNA in a
sequence-specific manner and is involved in neural specifica-
tion during embryogenesis (Cubelos et al., 2010; Bachy et al.,
2011); it may also be involved in regulation of the sex-specific
gene expression in female liver (Conforto et al., 2012). STAG2
is a component of cohesin complex, which is required for the
cohesion of sister chromatids after DNA replication (Prieto et
al., 2002).
Based on our results, we propose a panel of potential
hiPSC protein markers from the above-mentioned 22
proteins (Supplementary Table 12). We intentionally used
three previously characterized stem cell lines (hiPSC:
iNC-01, SB5-MP1 and hESC-H9) in our proteomic study.
The genomic methylation profile of the two cell lines
(hiPSC-iNC-01 and hESC-H9) has been previously studied
and found to be indistinguishable (Merling et al., 2013).
iNC-01, used to obtain functional neutrophils (Sweeney et
al., 2014) and SB5-MP1, was successfully used in differen-
tiation into motor neurons (Grunseich et al., 2014).
Therefore, the selection of hiPSC markers was done using
the cell lines, which underwent considerable functional
assays.
This protein marker panel was evaluated in nine additional
hiPSC lines or passages derived from different somatic cells
and by different reprogramming techniques. All the proteins
selected as the candidates for the protein marker panel for
hiPSC characterization were confirmed to be differentially
expressed in all analyzed hiPSCs compared to somatic cells. In
addition to that, our recent proteomic analysis of hiPSC and
embroid bodies (EBs) derived from them during the course of
spontaneous differentiation at 24 h and 7 days revealed that
the majority of the selected candidates to hiPSC markers are
dramatically down-regulated upon differentiation (in EB-24 h
and EB-7 days compare to hiPSC). These data (manuscript in
preparation) will serve as an additional confirmation of these
candidate marker proteins to be selected for hiPSC charac-
terization panel.Conclusions
Our study highlights the signaling pathways up-regulated in
both analyzed hiPSC lines after reprogramming, some ofwhich
are consistent with previously published data, but some are
contrasting to the data previously described for iPSC. In spite
of their different somatic origins (adult skin fibroblasts and
CD34+ hematopoietic stem cells), the biological functions
affected by the up-regulated proteins in both hiPSCs over-
lapped significantly.
336 N.S. Pripuzova et al.Based on the proteomic data obtained from two hiPSC
lines of different somatic origins at different passage levels
we selected a panel of previously described and novel hESC/
hiPSC protein markers. The possible extension, development
and further evaluation of this panel should facilitate the
improvement in hiPSC quality control assays and potential
clinical application of hiPSC.
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